Open AccessPharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
Author(s) -
Gian Paolo Fadini,
Mayur Sarangdhar,
Angelo Avogaro
Publication year - 2018
Publication title -
diabetes therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 33
ISSN - 1869-6961
DOI - 10.1007/s13300-018-0408-2
Subject(s) - pharmacovigilance , medicine , moderation , heart failure , diabetes mellitus , drug , pharmacology , endocrinology , psychology , social psychology
In the SAVOR-TIMI trial, the risk of heart failure (HF) was increased by 27% in T2D patients randomized to the dipeptidyl peptidase-4 inhibitor (DPP4i) saxagliptin. Other studies have provided inconsistent results regarding this association. Herein, we performed a pharmacovigilance analysis of the rate of HF associated with DPP4is, focusing on stimulated reporting and moderation by drug-drug interactions.